• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经皮胆道引流的临床结局与生活质量评估:一项前瞻性观察性研究。

Clinical outcomes of percutaneous biliary drainage and quality of life assessment: a prospective observational study.

作者信息

Sahoo Biswajit, Mane Krantisurya, Panigrahi Manas Kumar, Mishra Sourav Kumar, Barik Sandip Kumar, Majumdar Saroj Kumar Das, Nayak Manoj Kumar, Lohiya Ayush, Swain Phanindra Kumar, Nayak Hemanta Kumar, Das Deepak Kumar, Pitchaimuthu Arunprakash, Muduly Dillip Kumar, Naik Suprava, Gamanagatti Shivanand, Sasmal Prakash Kumar, Kumar Pankaj, Kar Madhabananda

机构信息

All India Institute of Medical Sciences Bhubaneswar, Bhubaneswar, India.

Kalyan Singh Super Speciality Cancer Institute, Lucknow, India.

出版信息

Abdom Radiol (NY). 2025 Jul 25. doi: 10.1007/s00261-025-05140-2.

DOI:10.1007/s00261-025-05140-2
PMID:40711566
Abstract

BACKGROUND

Percutaneous transhepatic biliary drainage (PTBD) is a widely used palliative intervention to relieve symptoms and reduce bilirubin levels to facilitate further treatments. However, data regarding its clinical outcomes and impact on quality of life (QOL), particularly in the Indian population, are limited. This prospective observational study intends to analyze the clinical outcomes, complication profile, factors affecting the clinical outcomes, and QOL assessment following PTBD in patients with malignant biliary obstruction (MBO).

METHODS

175 patients with MBO who underwent PTBD between March 2023 and August 2024 were enrolled in the study. The primary outcomes assessed included technical and clinical success following PTBD. The secondary outcomes comprised QOL evaluations using the European Organisation for Research and Treatment of Cancer Quality of Life questionnaire-BIL21, with follow-ups at 1 week, 1 month, and 3 months, as well as an examination of the factors influencing clinical success. Statistical analyses involved descriptive statistics, paired sample t-tests, bivariate and multivariate regression analyses, and Wilcoxon signed-rank tests, with p-values of less than 0.05 considered significant.

RESULTS

Technical success, defined as the correct catheter placement with bile drainage, was achieved in all cases (100%). Clinical success was observed in 81.6% of patients, with a significant reduction in median serum bilirubin from 15.67 mg/dL (IQR 8.91) at baseline to 3.9 mg/dL (IQR 2.9) at 4 weeks (p < 0.001). QOL improved significantly, particularly in eating, jaundice, tiredness, drainage tube, and weight loss scales, as measured at 1 month (p < 0.001). Complications were recorded in 76 (76/152, 50%) of cases, primarily consisting of minor complications such as peri-catheter leakage 52 (52/152, 34.2%) and major complications including cholangitis or sepsis 17(17/152, 11.2%), hemorrhage 2(2/152, 1.3%), and pancreatitis 1(1/152, 0.7%). In the multivariate regression analysis, age (p = 0.035) and liver metastases (p = 0.005) were significantly associated with clinical success. The Kaplan-Meier survival analysis indicated a median survival of 115 days (95% CI, 38.6-191.4, p = 0.025), compared to 46 days (95% CI, 0-103.4, p = 0.025) in the non-successful counterpart.

CONCLUSION

PTBD is a safe and effective option for managing MBO. Factors such as age at presentation and liver metastases status were found to be significantly associated with the clinical success of PTBD, while ECOG status, level of biliary obstruction, and unilobar or bilobar drainage were not significant. Therefore, it is advisable to consider these factors before proceeding with the PTBD procedure. There is a notable long-term difference in QOL post-PTBD, particularly regarding the jaundice and tiredness scales.

摘要

背景

经皮肝穿刺胆道引流术(PTBD)是一种广泛应用的姑息性干预措施,用于缓解症状并降低胆红素水平,以利于进一步治疗。然而,关于其临床结局以及对生活质量(QOL)的影响的数据有限,尤其是在印度人群中。这项前瞻性观察性研究旨在分析恶性胆管梗阻(MBO)患者接受PTBD后的临床结局、并发症情况、影响临床结局的因素以及生活质量评估。

方法

2023年3月至2024年8月期间接受PTBD的175例MBO患者纳入本研究。评估的主要结局包括PTBD后的技术成功和临床成功。次要结局包括使用欧洲癌症研究与治疗组织生活质量问卷-BIL21进行生活质量评估,在1周、1个月和3个月进行随访,以及检查影响临床成功的因素。统计分析包括描述性统计、配对样本t检验、双变量和多变量回归分析以及Wilcoxon符号秩检验,p值小于0.05被认为具有统计学意义。

结果

所有病例(100%)均实现技术成功,即导管放置正确且胆汁引流顺畅。81.6%的患者观察到临床成功,中位血清胆红素从基线时的15.67mg/dL(四分位间距8.91)显著降至4周时的3.9mg/dL(四分位间距2.9)(p<0.001)。生活质量有显著改善,尤其是在1个月时测量的饮食、黄疸、疲劳、引流管和体重减轻量表方面(p<0.001)。76例(76/152,50%)病例记录有并发症,主要包括轻微并发症,如导管周围渗漏52例(52/152,34.2%),以及严重并发症,包括胆管炎或败血症17例(17/152,11.2%)、出血2例(2/152,1.3%)和胰腺炎1例(1/152,0.7%)。在多变量回归分析中,年龄(p=0.035)和肝转移(p=0.005)与临床成功显著相关。Kaplan-Meier生存分析表明,中位生存期为115天(95%置信区间,38.6 - 191.4,p=0.025),而未成功组为46天(95%置信区间,0 - 103.4,p=0.025)。

结论

PTBD是治疗MBO的一种安全有效的选择。发现就诊时年龄和肝转移状态等因素与PTBD的临床成功显著相关,而东部肿瘤协作组(ECOG)状态、胆管梗阻水平以及单叶或双叶引流则无显著关联。因此,在进行PTBD手术前考虑这些因素是明智的。PTBD术后生活质量存在显著的长期差异,尤其是在黄疸和疲劳量表方面。

相似文献

1
Clinical outcomes of percutaneous biliary drainage and quality of life assessment: a prospective observational study.经皮胆道引流的临床结局与生活质量评估:一项前瞻性观察性研究。
Abdom Radiol (NY). 2025 Jul 25. doi: 10.1007/s00261-025-05140-2.
2
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状荟萃分析。
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.
3
Comparison of efficacy and complications of endoscopic and percutaneous biliary drainage in malignant obstructive jaundice: a systematic review and meta-analysis.内镜下与经皮经肝胆道引流治疗恶性梗阻性黄疸的疗效及并发症比较:一项系统评价与Meta分析
Cancer Imaging. 2017 Oct 16;17(1):27. doi: 10.1186/s40644-017-0129-1.
4
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
5
Home treatment for mental health problems: a systematic review.心理健康问题的居家治疗:一项系统综述
Health Technol Assess. 2001;5(15):1-139. doi: 10.3310/hta5150.
6
Endoscopic Biliary Drainage Versus Percutaneous Transhepatic Biliary Drainage in Patients with Resectable Hilar Cholangiocarcinoma: A Systematic Review and Meta-Analysis.可切除性肝门部胆管癌患者内镜下胆道引流与经皮经肝胆道引流的系统评价和Meta分析
J Laparoendosc Adv Surg Tech A. 2018 Sep;28(9):1053-1060. doi: 10.1089/lap.2017.0744. Epub 2018 Mar 12.
7
Sertindole for schizophrenia.用于治疗精神分裂症的舍吲哚。
Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2.
8
Maternal and neonatal outcomes of elective induction of labor.择期引产的母婴结局
Evid Rep Technol Assess (Full Rep). 2009 Mar(176):1-257.
9
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状Meta分析。
Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3.
10
Levetiracetam add-on for drug-resistant focal epilepsy: an updated Cochrane Review.左乙拉西坦添加治疗耐药性局灶性癫痫:Cochrane系统评价的更新版
Cochrane Database Syst Rev. 2012 Sep 12;2012(9):CD001901. doi: 10.1002/14651858.CD001901.pub2.

本文引用的文献

1
Prediction of effective percutaneous transhepatic biliary drainage in patients with hepatocellular carcinoma: A multi-central retrospective study.肝细胞癌患者有效经皮肝穿刺胆道引流的预测:一项多中心回顾性研究。
Liver Res. 2022 Dec 5;6(4):269-275. doi: 10.1016/j.livres.2022.11.008. eCollection 2022 Dec.
2
Radiofrequency ablation via catheter and transpapillary access in patients with cholangiocarcinoma (ACTICCA-2 trial) - a multicenter, randomized, controlled, open-label investigator-initiated trial.经皮经肝射频消融联合胆管内射频消融与单独经皮经肝射频消融治疗肝内胆管细胞癌的多中心随机对照临床试验(ACTICCA-2 研究)
BMC Cancer. 2024 Aug 1;24(1):931. doi: 10.1186/s12885-024-12693-w.
3
Correlation between functional drainage and survival in malignant biliary obstruction after percutaneous biliary drainage.
经皮胆道引流术后恶性胆道梗阻患者功能性引流与生存的相关性
Heliyon. 2024 Jan 8;10(2):e24088. doi: 10.1016/j.heliyon.2024.e24088. eCollection 2024 Jan 30.
4
Chemotherapy-associated liver morphological changes in hepatic metastases (CALMCHeM).化疗相关的肝转移瘤形态学改变(CALMCHeM)。
Diagn Interv Radiol. 2023 Jul 20;29(4):571-578. doi: 10.4274/dir.2023.232299. Epub 2023 Jun 13.
5
Short and long outcomes of endoscopic bilateral metal stent placement for malignant hilar biliary obstruction: Tertiary care oncology centre experience.内镜下双侧金属支架置入治疗恶性肝门部胆管梗阻的短期和长期疗效:三级肿瘤治疗中心的经验。
Indian J Gastroenterol. 2023 Jun;42(3):396-403. doi: 10.1007/s12664-022-01337-1. Epub 2023 May 18.
6
Percutaneous transhepatic biliary drainage for biliary obstruction in perihilar cholangiocarcinoma: a 10-year analysis of safety and outcomes using the CCI index.经皮经肝胆道引流治疗肝门部胆管癌所致胆道梗阻:使用CCI指数的10年安全性和疗效分析
Langenbecks Arch Surg. 2023 Feb 27;408(1):109. doi: 10.1007/s00423-023-02852-1.
7
Diagnosing malignant distal bile duct obstruction using artificial intelligence based on clinical biomarkers.基于临床生物标志物的人工智能诊断恶性远端胆管梗阻。
Sci Rep. 2023 Feb 24;13(1):3262. doi: 10.1038/s41598-023-28058-5.
8
The Clinical Benefit of Percutaneous Transhepatic Biliary Drainage for Malignant Biliary Tract Obstruction.经皮经肝胆道引流术治疗恶性胆道梗阻的临床疗效
Cancers (Basel). 2022 Sep 26;14(19):4673. doi: 10.3390/cancers14194673.
9
Percutaneous transhepatic cholangiography endoscopic ultrasound-guided biliary drainage: A systematic review.经皮经肝胆管造影术与内镜超声引导下胆汁引流术:系统评价。
World J Gastroenterol. 2022 Jul 21;28(27):3514-3523. doi: 10.3748/wjg.v28.i27.3514.
10
Percutaneous biliary drainage for obstructive jaundice in patients with inoperable, malignant biliary obstruction.经皮胆道引流术治疗无法手术的恶性胆道梗阻患者的梗阻性黄疸
Clin Exp Hepatol. 2022 Mar;8(1):70-77. doi: 10.5114/ceh.2022.114190. Epub 2022 Mar 23.